Categories Earnings, Health Care

Dynavax Technologies Corporation (NASDAQ: DVAX): Q4 2019 Earnings Snapshot

— Biopharmaceutical company Dynavax Technologies Corporation (NASDAQ: DVAX) reported a net loss of $36.8 million $0.44 per share for the fourth quarter of 2019, vs. $0.33 per share loss expected.

— Total sales more than doubled year-over-year to $10.57 million, vs. $11.96 million expected

— Research and development expenses dropped to $12.3 million in the fourth quarter from $22.9 million last year

— Established research collaboration with the University of Queensland and the Coalition for Epidemic Preparedness to develop coronavirus vaccine

— Appointed Ryan Spencer chief executive officer and to the board of directors; named David Novack president and chief operating officer

— Expects HEPLISAV-B net product revenue to increase to $55-$62 million in fiscal 2020

— On track to release interim data from ongoing study of HEPLISAV-B in hemodialysis patients in the first quarter

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

360 DigiTech (NASDAQ: QFIN) Q3 2021 Research Summary

The positive effects of widespread digitalization and e-commerce growth on China’s financial services industry became more pronounced during the pandemic as the movement restrictions drove more retail customers to online

Activision Blizzard (ATVI): Three reasons why this stock deserves to be on your radar

Shares of Activision Blizzard Inc. (NASDAQ: ATVI) were up 1.6% on Thursday. The stock has dropped 14% since the start of the year. The company has been in the news

IPO Alert: Here’s all you need to know about Remitly Global’s upcoming market debut

The emergence of technology-driven financial services is making people think beyond conventional banks when it comes to availing loans and transferring funds. In a move aimed at taking its business

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top